• 5 WEST 2.18

Accepting Doctoral Students

If you made any changes in Pure these will be visible here soon.

Personal profile

Willing to supervise doctoral students

and PostDocs

I welcome motivated PhD students and PostDocs with a biological science background who are interested in cancer biology and drug discovery. If you would like to apply for a scholarship to join my lab please contact me well in advance.

Research interests

Our research aims to identify novel strategies to target the tumour and/or stroma for the prevention or suppression of metastatic cancer and to overcome treatment-resistant tumour progression focusing on the role of normal and cancer-associated fibroblasts in breast and skin cancer. By combining cancer and metastasis models with in vitro 2D/3D co-culture systems we address the role of fibroblasts on therapy resistance and drug activity, but also how therapies impact fibroblasts and their pro- and anti-tumourigenic phenotypes. 


Metastatic Cancer and the microenvironment

The majority of cancer-related deaths are due to metastatic disease. Despite advances in identifying major drivers of primary tumour growth and the development of novel targeted therapies, there remains an unmet clinical need to develop treatment strategies targeting metastatic disease and intrinsic and acquired resistance. It is now well established that successful tumour progression involves a close crosstalk between tumour cells and the stromal microenvironment, including fibroblasts, pericytes, endothelial and immune cells but also the extracellular matrix (ECM). Furthermore, there is growing evidence that the stroma can modulate therapy resistance. 


Current lab members:

Emily Lay (PhD student)

Ioanna Kontou (PhD student)


Former lab members:

Simone Herwig (ERASMUS visiting student)

Laura Edwards (BSc BMS, final year project, 2021/22)

Sabrina James (BSc BMS, final year project, 2021/22)

Spyroula Antoniou (MSc Drug Discovery, 2021)

Anna Lauridsen (ERASMUS visiting student, 2018/19)

Mari Davies (BSc BMS, final year project, 2019/20)

Meryl Attrill (BSc BMS, final year project, 2019/20) 

Shujun Wang (MSc Drug Discovery, 2020)



Dr Ute Jungwirth holds a master’s degree (Magistra rerum naturalium) in Chemistry from the University Vienna and in Toxicology (MScTox) from the Medical University Vienna. She carried out her PhD at the Institute of Cancer Research at the Medical University Vienna (Austria) in the group of Professor Walter Berger

In 2013 she was awarded a Schrödinger Postdoctoral Fellowship from the Austrian Science Fund to join the group of Professor Clare Isacke at the Institute of Cancer Research ICR London, UK. Her research focused on the metastasis-promoting role of cancer-associated fibroblasts and she developed a syngeneic, spontaneously metastasising breast cancer in vivo model and the collagen receptor Endo180.

Dr Ute Jungwirth is Chair of the Cancer Research at Bath CR@B committee and network and member of the Centre of Therapeutic Innovations CTI at the Unviersity of Bath.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Education/Academic qualification

Malignant Diseases, Doctor of Philosophy, Medical University of Vienna

Toxicology, Master of Science, Medical University of Vienna

Chemistry, Master of Chemistry, University of Vienna


Dive into the research topics where Ute Jungwirth is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles


Recent external collaboration on country/territory level. Dive into details by clicking on the dots or